GlassScriptPhysician profile
Denine Raymond
NPI 1528611357
$8,605.89
in general payments reported to CMS, 2019-2025
43 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,640 · 2022: $3,331 · 2023: $2,510 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,577.30 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $824.73 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $669.39 | 2021-2023 | |
| Lilly USA, LLC | $636.53 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $494.78 | 2021-2023 | Veozah, Myrbetriq |
| Amgen INC. | $467.57 | 2021-2023 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.42 | 2021-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $245.82 | 2021-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $245.24 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $243.37 | 2021-2023 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $225.31 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.69 | 2021-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $212.69 | 2021-2023 | |
| Mylan Specialty L.P. | $182.19 | 2021-2023 | Yupelri |
| Esperion Therapeutics, INC. | $177.57 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denine Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.